Zobrazeno 1 - 10
of 44
pro vyhledávání: '"DAVID COEFFIC"'
Autor:
Bruno Coudert, Jean-Yves Pierga, Marie-Ange Mouret-Reynier, Kaldoun Kerrou, Jean-Marc Ferrero, Thierry Petit, Fanny Le Du, Pierre-François Dupré, Thomas Bachelot, Philippe Gabelle, Marie-Pierre Chauvet, David Coeffic, Catherine Barbe, Jean-Briac Prevost, Gilles Paintaud, Gilles Thibault, Abdennour Ferhat, Julien Dupin, Alina Berriolo-Riedinger, Laurent Arnould
Publikováno v:
EClinicalMedicine, Vol 28, Iss , Pp 100566- (2020)
Background: The open-label, randomised Phase 2 AVATAXHER study (NCT01142778) demonstrated that early PET assessment identified HER2-positive breast cancer patients who responded poorly to neoadjuvant docetaxel plus trastuzumab. Adding neoadjuvant bev
Externí odkaz:
https://doaj.org/article/e12828e210e34b18a595bb3ec526544b
Autor:
HELOÏSE BOURIEN, LEÏLA BENGRINE LEFEVRE, MARIE-ANGE MOURET-REYNIER, BERNARD ASSELAIN, BRIGITTE LUCAS, CELINE GAVOILLE, CORINA CORNILA, LAURENE GAVOILLE, EMELINE COLOMBA, ANNE PATSOURIS, MICHEL FABBRO, CAMILLE CHAKIBA, PHILIPPE TOUSSAINT, HELENE SIMON, DOMINIQUE BERTON, DELPHINE GARBAY, CLAIRE GARNIER TIXIDRE, DAVID COEFFIC, AURELIE MORVAN, OLIVIER COLLARD, THIBAULT DE LA MOTTE ROUGE
Publikováno v:
Anticancer Research. 43:653-662
Publikováno v:
Bulletin du Cancer. 107:745-755
Resume Contexte et rationnel Bien que la mise a disposition du trastuzumab ait considerablement ameliore le pronostic des cancers du sein precoces HER2+, des recidives sont observees notamment dans certains sous-groupes de patientes. L’objectif de
Autor:
Camille Mazza, Vincent Gaydou, Jean-Christophe Eymard, Philippe Birembaut, Valérie Untereiner, Jean-François Côté, Isabelle Brocheriou, David Coeffic, Philippe Villena, Stéphane Larré, Vincent Vuiblet, Olivier Piot
Publikováno v:
Cancers
Cancers, Vol 14, Iss 21, p 21 (2022)
Cancers, Vol 14, Iss 21, p 21 (2022)
Simple Summary Assessing the tumor response to chemotherapy is a paramount predictive step to improve patient care. Infrared spectroscopy probes the chemical composition of samples, and in combination with statistical multivariate processing, present
Autor:
Jean-Yves Pierga, Alina Berriolo-Riedinger, Thierry Petit, Laurent Arnould, David Coeffic, Abdennour Ferhat, Gilles Paintaud, Jean-Briac Prevost, Pierre-Francois Dupre, Fanny Le Du, Thomas Bachelot, Marie-Pierre Chauvet, Jean-Marc Ferrero, Gilles Thibault, Kaldoun Kerrou, Philippe Gabelle, Catherine Barbe, Julien Dupin, Bruno Coudert, Marie-Ange Mouret-Reynier
Publikováno v:
EClinicalMedicine
EClinicalMedicine, Elsevier, 2020, 28, pp.100566. ⟨10.1016/j.eclinm.2020.100566⟩
EClinicalMedicine, Vol 28, Iss, Pp 100566-(2020)
EClinicalMedicine, 2020, 28, pp.100566. ⟨10.1016/j.eclinm.2020.100566⟩
EClinicalMedicine, Elsevier, 2020, 28, pp.100566. ⟨10.1016/j.eclinm.2020.100566⟩
EClinicalMedicine, Vol 28, Iss, Pp 100566-(2020)
EClinicalMedicine, 2020, 28, pp.100566. ⟨10.1016/j.eclinm.2020.100566⟩
Background: The open-label, randomised Phase 2 AVATAXHER study (NCT01142778) demonstrated that early PET assessment identified HER2-positive breast cancer patients who responded poorly to neoadjuvant docetaxel plus trastuzumab. Adding neoadjuvant bev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca4465ae59def55372fbfb42d70b2eac
https://hal.sorbonne-universite.fr/hal-03244169/document
https://hal.sorbonne-universite.fr/hal-03244169/document
Background Despite improved prognosis of HER2+ eBC since the introduction of trastuzumab in the adjuvant setting in 2006, disease recurrences still occur in some patients after a few years. We aimed to describe in real life the long-term follow-up to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bd4666bca39f66f0f20ccf64058646c1
https://doi.org/10.21203/rs.2.14778/v2
https://doi.org/10.21203/rs.2.14778/v2
Background Despite improved prognosis of HER2+ eBC since the introduction of trastuzumab in the adjuvant setting in 2006, disease recurrences still occur in some patients after a few years. We aimed to describe in real life the long-term follow-up to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fc195e0bcedffb2c3770f3790c9b95df
https://doi.org/10.21203/rs.2.14778/v1
https://doi.org/10.21203/rs.2.14778/v1
Autor:
Pierre-Francois Dupre, Marie-Pierre Chauvet, Jean Marc Ferrero, David Coeffic, Jean-Briac Prevost, Thomas Bachelot, Thierry Petit, Alina Berriolo-Riedinger, Catherine Barbe, Julien Dupin, Gilles Paintaud, Kaldoun Kerrou, Philippe Gabelle, Laurent Arnould, Jean-Yves Pierga, Fanny Le Du, Marie-Ange Mouret-Reynier, Bruno Coudert, Abdennour Ferhat
Publikováno v:
SSRN Electronic Journal.
Background: The open-label, randomised Phase 2 AVATAXHER study demonstrated that early PET assessment identified patients with HER-2 positive breast cancer who responded poorly to standard neoadjuvant therapy (docetaxel plus trastuzumab). Adding beva
Autor:
Olfa Derbel, Julien Dupin, Luis Augusto Teixeira, Christelle Levy, David Coeffic, Nazario Esposito, Rim Ghorbal
Publikováno v:
Journal of Clinical Oncology. 38:e14107-e14107
e14107 Background: There is increasing interest in using e-health systems for symptom monitoring and alert triggering. ZEMY, a new software medical device, was developed to improve symptom management and enhance patient and health care team interacti
Autor:
Isabelle Desmoulins, Hans Wildiers, Thomas Bachelot, Tan Winston, Anne Laure Martin, Paul Cottu, Jean-Luc Canon, Magali Lacroix-Triki, François Duhoux, H. Orfeuvre, Bernard Asselain, David Coeffic, Didier Verhoeven, Marc Spielmann, Lise Roca, Henri Roché, Pierre Kerbrat, Mario Campone, Jean-Christophe Eymard, Jérôme Lemonnier, Dominique Jaubert, Christelle Levy, Lionel Uwer
Publikováno v:
European journal of cancer
Purpose: UNICANCER-PACS08 compared adjuvant FEC (5-FU; epirubicin; cyclophosphamide) then docetaxel to FEC then ixabepilone in poor prognosis early breast cancer (BC). We evaluated whether replacing docetaxel with ixabepilone would increase 5-year di